Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

The American Journal of Cardiology is a leading peer-reviewed journal in the field of Cardiology and Cardiovascular Medicine, published by Excerpta Medica Inc-Elsevier Science Inc. Since its inception in 1958, the journal has consistently contributed to the advancement of cardiovascular research, providing a platform for groundbreaking studies and clinical findings that shape modern medical practices. With an impressive impact factor placing it in the Q1 category in its field for 2023, it ranks among the top journals in medicine, with a rank of #155 out of 387 in the Scopus database, reflecting its significance and rigorous editorial standards. The journal is committed to disseminating high-quality research that fosters innovation and enhances clinical outcomes in cardiology. Although it does not provide Open Access options, the American Journal of Cardiology remains an essential resource for researchers, healthcare professionals, and students looking to deepen their understanding of cardiovascular health.

Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.

Future Cardiology, published by Future Medicine Ltd, is an esteemed journal dedicated to advancing the field of cardiology and cardiovascular medicine. With an ISSN of 1479-6678 and an E-ISSN of 1744-8298, this journal has been serving as a vital platform for researchers and healthcare professionals since its inception in 2006. The journal features rigorously peer-reviewed articles, offering insights into innovative treatments, clinical studies, and cutting-edge research developments. Although it is currently categorized as Q3 in Cardiology and Cardiovascular Medicine and Q4 in Molecular Medicine, its growing impact is evident in its dedicated audience and commitment to fostering dialogue in the cardiovascular community. Future Cardiology provides an invaluable opportunity for scholars to share their findings and enhance knowledge in this critical area of healthcare, a pursuit that is ever more important as cardiovascular diseases continue to be a leading health concern worldwide. Access options are through standard subscriptions, allowing in-depth exploration of articles that push the boundaries of cardiological science.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

American Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.